Prostate cancer progression after therapy of primary curative intent: A review of data from the prostate-specific antigen era

Cancer

Volumn 104, Issue 11, 2005, Pages 2310-2322

  Soloway, Mark ^a   Roach III, Mack ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brachytherapy; Disease progression; Disease stage; Gleason score; Prostate cancer; Prostate specific antigen; Radical prostatectomy; RT

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CARCINOGENESIS; DISEASE COURSE; EARLY CANCER; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RISK ASSESSMENT; RISK FACTOR;

BRACHYTHERAPY; CLINICAL TRIALS; DISEASE PROGRESSION; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 28044434387     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21441     Document Type: Review

References (55)

1. Mettlin CJ, Murphy GP, Rosenthal DS, et al. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679-1684.
2. Zagars GK, Pollack A, von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 1997;80:764-775.
3. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168-172.
4. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
5. Graefen M, Noldus J, Pichlmeier U, et al. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999;36:21-30.
6. Lieberfarb ME, Schultz D, Whittington R, et al. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:898-903.
7. Pollack A, Smith LG, von Eschenbach AC. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys. 2000;48:507-512.
8. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase 111 randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105.
9. Hanks GE, Hanlon AL, Pinover WH, et al. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 2000;46:823-832.
10. Zietman AL, Thakral H, Wilson L, et al. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. J Urol. 2001;166:1702-1706.
11. Ullrich PM, Carson MR, Lutgendorf SK, et al. Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. J Urol. 2003;169:1449-1452.
12. Smith Jr JA, Soloway MS, Young MJ. Complications of advanced prostate cancer. Urology 54(suppl 6A):8-14, 1999.
13. Penson DF, Moul JW, Evans CP, et al. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol. 2004;171:2250-2254.
14. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553-561.
15. Connell PP, Ignacio L, McBride RB, et al. Caution in interpreting biochemical control rates after treatment of prostate cancer: length of follow-up influences results. Urology. 1999;54:875-879.
16. Cavanagh W, Blasko JC, Grimm PD, et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol. 2000;18:160-165.
17. Vicini FA, Martinez A, Hanks G, et al. An interinstitutional and interspecialty comparison of treatment outcome data for patients with prostate carcinoma based on predefined prognostic categories and minimum follow-up. Cancer. 2002;95:2126-2135.
18. Hull GW, Rabbani F, Abbas F, et al. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002;167:528-534.
19. Brachman DG, Thomas T, Hilbe J, et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice. Int J Radiat Oncol Biol Phys. 2000;48:111-117.
20. Lee WR, Hanks GE, Schultheiss TE, et al. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol. 1995;13:464-469.
21. Roberts SG, Blute ML, Bergstralh EJ, et al. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001;76:576-581.
22. Moul JW, Connelly RR, Lubeck DP, et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol. 2001;166:1322-1327.
23. Oberpenning F, Hamm M, Schmid HP, et al. Radical prostatectomy: survival outcome and correlation to prostate-specific antigen levels. Anticancer Res. 2000;20:4969-4972.
24. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165:1146-1151.
25. Wheeler TM, Dillioglugil O, Kattan MW, et al. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol. 1998;29:856-862.
26. Han M, Partin AW, Piantadosi S, et al. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol. 2001;166:416 -419.
27. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer Staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001;88:702-707.
28. Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol. 1996;20:286-292.
29. Babaian RJ, Troncoso P, Bhadkamkar VA, et al. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer. 2001;91:1414-1422.
30. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
31. Amling CL, Blute ML, Lerner SE, et al. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998;73:401-406.
32. Shipley WU, Thames HD, Sandier HM, et al. Radiation therapy for clinically localized prostate cancer. A multi-institutional pooled analysis. JAMA. 1999;281:1598-1604.
33. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997;79:1370-1380.
34. Hanlon AL, Hanks GE. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure. Cancer J. 2000;6(suppl 2):S193-S197.
35. Lawton CA, Winter K, Murray K, et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;49:937-946.
36. Zagars GK, Ayala AG, von Eschenbach AC, et al. The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1995;31:237-245.
37. Catton C, Gospodarowicz M, Mui J, et al. Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol. 2002;9:1444-1452.
38. Horwitz EM, Vicini FA, Ziaja EL, et al. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 1996;36:565-571.
39. Kupelian PA, Elshaikh M, Reddy CA, et al. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002;20:3376-3385.
40. Zietman AL, Tibbs MK, Dallow KC, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 1996;40:159-162.
41. Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol. 2002;167:1310-1313.
42. Lederman GS, Cavanagh W, Albert PS, et al. Retrospective stratification of a consecutive cohort of prostate cancer patients treated with a combined regimen of external-beam radiotherapy and brachytherapy. Int J Radiat Oncol Biol Phys. 2001;49:1297-1303.
43. Hanks GE, Hanlon AL, Pinover WH, et al. Survival advantage for prostate cancer patients treated with high-dose three-dimensional conformal radiotherapy. Cancer J Sci Am. 1999;5:152-158.
44. Ragde H, Grado GL, Nadir BS. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone. Arch Esp Urol. 2001;54:739-747.
45. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280-1283.
46. Zelefsky MJ, Fuks Z, Hunt M, et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol. 2001;166:876-881.
47. Chuba PJ, Moughan J, Forman JD, et al. The 1989 patterns of care study for prostate cancer: five-year outcomes. Int J Radiat Oncol Biol Phys. 2001;50:325-334.
48. Blasko JC, Grimm PD, Sylsvester JE, et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57:273-278.
49. Roach Spaceiiiqq M, Weinberg V, McLaughlin PW, et al. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003;61:730-735.
50. Roach Spaceiiiqq M, Lu J, Pilepich MV, et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys. 2000;47:609-615.
51. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103-108.
52. Pilepich MV, Winter K, Lawton C, et al. Phase Spaceiiiqq trial of androgen suppression adjuvant to definitive radiotherapy. Long term results of RTOG study 85-31. [abstract 153O]. Proc Am Soc Clin Oncol. 2003;22:381.
53. Hanks GE, Pajak TF, Porter A, et al. Phase Spaceiiiqq trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-3978.
54. Granfors T, Modig H, Damber J-E, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol. 1998;159:2030-2034.
55. Messing E, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886 [abstract 1480]. J Urol 2003;169:396.